Xtl Biopharmaceuticals (XTLB) Revenue (2011 - 2024)

Xtl Biopharmaceuticals (XTLB) posted Revenue of $289000.0 for Q4 2024, down 71.94% sequentially from $1.0 million in Q3 2018.

Analysis

Xtl Biopharmaceuticals (XTLB) Revenue (2011 - 2024) Analysis & Trends

Xtl Biopharmaceuticals has reported Revenue for 7 years, with the latest figure at $289000.0 in Q4 2024.

Quarterly Revenue changed N/A year-over-year to $289000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.2 million (changed N/A YoY) and the FY2025 annual result came in at -$549000.0, down 221.73% from the prior year.
Revenue fell to $289000.0 in Q4 2024 per XTLB's latest filing, from $1.0 million in the prior quarter.
Over five years, Revenue peaked at $289000.0 in Q4 2024 and troughed at $289000.0 in Q4 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	140.22 Bn	132.37 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	86.04 Bn	78.05 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	63.70 Bn	58.52 Bn	1.37 Bn	1.52 Bn
4	Moderna	57.56 Bn	52.42 Bn	52.00 Mn	145.00 Mn
5	Revolution Medicines	44.05 Bn	44.05 Bn	-	-
6	BeOne Medicines	40.16 Bn	35.06 Bn	1.53 Bn	1.71 Bn
7	Alnylam Pharmaceuticals	35.63 Bn	32.32 Bn	992.69 Mn	1.29 Bn
8	Royalty Pharma	28.63 Bn	27.79 Bn	-	674.14 Mn
9	Insmed	27.73 Bn	26.57 Bn	358.27 Mn	425.49 Mn
10	Xtl Biopharmaceuticals	2.25 Bn	2.25 Bn	-	-

Historic Data

Download Data